| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62018d5da824da2c4e9b748f123afe0a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5cd8416a77ecb1970efabb73e4b4990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b15c9ca04abd71ac549938197199b227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_516e08dd45c4d311b03c03251b167bad |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020198160-A1 |
| titleOfInvention |
Targeted active gene editing agent and methods of use |
| abstract |
Methods and compositions related to intracellular delivery of gene editing proteins are provided. The invention relates to compositions and methods for transporting gene editing polypeptides, such as Cas9 or Cas12, into a cell ex vivo or in vivo. The invention includes a targeted active gene editing (TAGE) agent that includes an antigen binding polypeptide that specifically binds to an extracellular cell membrane-bound molecule, and a site-directed modifying polypeptide that recognizes a nucleic acid sequence. The antigen binding polypeptide and the site-directed modifying polypeptide are stably associated such that the site-directed modifying polypeptide can be internalized into a cell displaying the extracellular cell membrane-bound molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113045666-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113045666-B |
| priorityDate |
2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |